On the other hand, based on the results obtained in the context of other tumors (Brahmer et al., 2010; Eder and Kalman, 2014; Larkin et al., 2015; Weber et al., 2015; Kessler et al., 2018; Stathias et al., 2018), the use of programmed cell death protein (PD-1) receptor/programmed death ligand 1 (PD-L1) inhibitors has been suggested for gliomas, including GBM (Motzer et al., 2015; Goldberg et al., 2016; Reck et al., 2016; Schwartz et al., 2016; Reiss et al., 2017; Reardon et al., 2018; Cloughesy et al., 2019; Schalper et al., 2019). This evidence concerns the gene CD274 and glioblastoma.